Reduction of Remifentanil-related Complications by Limiting Maximum Plasma Concentration During Target-controlled Infusion

• Status: Unknown status
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is intended to evaluate the effect of decreasing the maximum plasma concentration target of remifentanil of the Target Controlled Infusion system on the the incidence of major and minor side-effects.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Remifentanil

Criteria

Inclusion Criteria:

• 18-70 year old

• ASA class 1-3 scheduled for elective surgery

Exclusion Criteria:

• history of neurologic or mental disorder

• uncontrolled pulmonary or cardiovascular disease

• history of adverse reactions to opioids

• history of drug abuse